MX9301387A - Metodo y composicion para el tratamiento de osteoporosis. - Google Patents

Metodo y composicion para el tratamiento de osteoporosis.

Info

Publication number
MX9301387A
MX9301387A MX9301387A MX9301387A MX9301387A MX 9301387 A MX9301387 A MX 9301387A MX 9301387 A MX9301387 A MX 9301387A MX 9301387 A MX9301387 A MX 9301387A MX 9301387 A MX9301387 A MX 9301387A
Authority
MX
Mexico
Prior art keywords
treatment
osteoporosis
composition
mammal
prevention
Prior art date
Application number
MX9301387A
Other languages
English (en)
Inventor
Hans-Peter Guler
Satish Bhatia
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of MX9301387A publication Critical patent/MX9301387A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para el tratamiento o prevención de la osteoporosis en mamíferos superiores, comprendiendo el método administrar el factor I de crecimiento, (IGF-I) parecido a insulina, en una cantidad efectiva del mismo, a dicho mamífero, cuando el mamífero tienen necesidad de dicho tratamiento o prevención. También se describen composiciones farmacéuticas para usarlas en el método anterior.
MX9301387A 1992-03-13 1993-03-12 Metodo y composicion para el tratamiento de osteoporosis. MX9301387A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85054592A 1992-03-13 1992-03-13

Publications (1)

Publication Number Publication Date
MX9301387A true MX9301387A (es) 1994-08-31

Family

ID=25308435

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9301387A MX9301387A (es) 1992-03-13 1993-03-12 Metodo y composicion para el tratamiento de osteoporosis.

Country Status (11)

Country Link
US (2) US6300309B1 (es)
EP (1) EP0560723A1 (es)
JP (1) JP3771280B2 (es)
KR (1) KR930019223A (es)
AU (1) AU666514B2 (es)
CA (1) CA2091534A1 (es)
IL (1) IL104940A0 (es)
MX (1) MX9301387A (es)
NZ (1) NZ247123A (es)
TW (1) TW267102B (es)
ZA (1) ZA931778B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504971A (ja) * 1994-09-08 1998-05-19 カイロン コーポレイション インスリン様増殖因子の改善された生産方法
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
DE60016560T2 (de) 1999-01-06 2005-12-15 Genentech, Inc., South San Francisco Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
DE60120372T2 (de) 2000-03-24 2007-07-05 Genentech Inc., San Francisco Verwendung von insulin zur behandlung von knorpelkrankheiten
DK1282437T3 (da) 2000-05-16 2008-06-30 Genentech Inc Behandling af brusklidelser
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
US8158582B2 (en) * 2005-06-02 2012-04-17 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 deficiency
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
EP1984016A1 (en) * 2006-02-17 2008-10-29 Associazione Foresta Per La Ricerca Nella Riproduzione Umana Use of insulin-like factor 3 for treating osteoporosis and bone disorders
US20080200425A1 (en) * 2007-02-16 2008-08-21 Kurtz Seymour J Methods and compositions for regulating bone mineral density
CN117442747A (zh) * 2017-05-21 2024-01-26 Igf肿瘤公司 胰岛素样生长因子——用于治疗骨髓增生异常综合症的化学治疗缀合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
EP0123228B1 (en) 1983-04-25 1993-09-29 Chiron Corporation Hybrid dna synthesis of mature insulin-like growth factors
CA1322714C (en) * 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
DE3851776T2 (de) 1987-04-28 1995-05-04 Boehringer Mannheim Gmbh Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
EP0386109A1 (en) 1987-11-12 1990-09-12 Schering Corporation Acceleration of bone formation with gm-csf
ZA9010332B (en) 1989-12-22 1991-08-28 Ciba Geigy Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
NZ236618A (en) * 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
JPH0818999B2 (ja) * 1990-01-05 1996-02-28 藤沢薬品工業株式会社 インシュリン様成長因子ｉの乾燥製剤
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation

Also Published As

Publication number Publication date
US6300309B1 (en) 2001-10-09
CA2091534A1 (en) 1993-09-14
TW267102B (es) 1996-01-01
AU3406893A (en) 1993-09-16
ZA931778B (en) 1993-09-13
IL104940A0 (en) 1993-07-08
NZ247123A (en) 1997-08-22
AU666514B2 (en) 1996-02-15
EP0560723A1 (en) 1993-09-15
KR930019223A (ko) 1993-10-18
JP3771280B2 (ja) 2006-04-26
JPH069429A (ja) 1994-01-18
US6358925B1 (en) 2002-03-19

Similar Documents

Publication Publication Date Title
MX9301387A (es) Metodo y composicion para el tratamiento de osteoporosis.
MX9304435A (es) Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii.
LV12284A (lv) No kudras izdaliti bioaktivi produkti un tos saturosas farmaceitiskas un kosmetiskas kompozicijas
EP0289314A3 (en) Use of igf-ii in the treatment of bone disorders
DE68919358D1 (de) Zusammensetzung zur behandlung der schizophrenie.
EP0730465A4 (en) USE OF ANGIOTENSIN III AND ITS ANALOGS FOR TISSUE REPAIR
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
MX9303554A (es) Peptido similar al glucagon y derivados de insulinotropina.
DE69533112D1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
MX9703609A (es) Uso de fragmentos de angiotensina ii y analogos de la misma para la preparacion de composiciones en la preparacion de tejido.
BR9106977A (pt) Metodo para suprimir destruicao autoimune de celuias beta pancreaticas,formulacao farmaceutica,metodo de profilaxia,metodo para prevenir o surgimento de diabetes tipo 1 e metodo para tratar um mamifero
RU94046291A (ru) Способ профилактики и лечения периферической невропатии, композиция, содержащая инсулин-подобный фактор роста i
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
DE69008476D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose.
MD1558F2 (en) Method of prophylaxis of mammal acute renal insufficiency utilizing IGF-I insulin-like growth factor
ES2151083T3 (es) Composiciones orales que contienen ondansetron.
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
RU94002337A (ru) Фармацевтическая композиция, применение гамма-линоленовой или дигомо-гамма-линоленовой кислоты для лечения поражений после облучения, способ лечения
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
RU93058532A (ru) Фармацевтическая композиция для остеоиндукции, способ генерации новой кости
NO934381L (no) Terapeutiske sammensetninger for osteoinduksjon
ES2174838T3 (es) Metodo para aumentar la absorcion del intestino.
CO5060499A1 (es) Metodos y composiciones para el tratamiento de enfermedad de reflujo gastroesofagico
UY26514A1 (es) " composición para el tratamiento de tejidos danados".
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS